Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

Evogene Schedules First Quarter 2024 Financial Results Release


Zoom conference call scheduled for 9:00 AM ET

REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.

Evogene Logo

Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_GBxR-LTZRYy9D7OIt2YW0g

The entire conference will be available online on the company's website a few days after.

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including:

  1. Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
  2. Lavie Bio Ltd. (www.lavie-bio.com) -  developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI;
  3. AgPlenus Ltd. (www.agplenus.com) -  developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
  4. Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
[email protected]
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg

SOURCE Evogene


These press releases may also interest you

at 09:35
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as...

at 09:30
Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
Tolmar Inc., a fully integrated pharmaceutical company, today announced results from a landmark survey of more than 300 US physicians, revealing...

at 08:42
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, will present a poster at the 2024 ASCO Annual Meeting entitled "Phase 1 study of BAT8006, a folate...

at 08:10
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) ?demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free...

at 08:05
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody...

at 08:05
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe
ASCO Annual Meeting ? Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today announced a partnership to significantly expand patient access to psycho oncology services,...

More news about Health...


News published on and distributed by: